Healthcare
Genentech completes $2 bln North Carolina biomanufacturing facility
Structural framework finished for Genentech's first East Coast plant, part of a $50 bln Roche commitment to U.S. biotech infrastructure. Facility to employ 2,000+ once operational.
Basilea Pharmaceutica posts 32% profit surge in H1 2026, raises guidance
Swiss drugmaker reports CHF 27.9 million net profit for the first half, driven by strong Cresemba sales and non-dilutive funding. Full-year outlook upgraded on revenue and profit growth.
Basilea Pharmaceutica lifts H1 2026 outlook as stock surges 8.7%
Swiss biotech raised its full-year revenue and profit guidance after reporting a 14% revenue jump in H1 2026. Shares rose 8.7% in pre-market trading.
DocMorris raises 2026 outlook after H1 Rx revenue growth accelerates
Swiss online pharmacy posts 38% H1 revenue growth as prescription volumes surge, lifting full-year guidance and targeting EBITDA breakeven by year-end.
Ambea posts 88% EPS gain, SEK 929m free cash flow in Q2 2026
Swedish care provider Ambea reported an 88% rise in adjusted EPS to SEK 2.13, while rolling 12-month free cash flow reached SEK 929m as EBITDA margins hit 10%. Shares rose 10.7%.
Francisco Partners to buy Weave for $650 million in cash
The deal values Weave at a 34% premium to its prior close and will take the healthcare software firm private in Q4 2026.
Galderma Secures EU Approval for Restylane Shaype Injectable
Galderma has obtained European Union approval for Restylane Shaype, a hyaluronic acid injectable designed for chin augmentation.